Evidence map›Paper›PMID 33776707›Full record

ArticleCase reports in oncology

Transformation of Acute Myeloid Leukemia with Deletion of Chromosome 7q and Additional Abnormalities in Chromosome 8 in a Patient with Essential Thrombocythemia.

Ayaka Shimizu, Kei Takenaka, Shinya Ohata, Kazuhide Morimoto, Hiromi Hashimoto, Yuki Yamamoto, Toshio Itoh, Takeshi Sugimoto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ayaka ShimizuDepartment of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan.
Kei TakenakaDepartment of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan.
Shinya OhataDepartment of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan.
Kazuhide MorimotoDivision of Clinical Laboratory, Kita-Harima Medical Center, Ono, Japan.
Hiromi HashimotoDivision of Clinical Laboratory, Kita-Harima Medical Center, Ono, Japan.
Yuki YamamotoDepartment of Diagnostic Pathology, Kita-Harima Medical Center, Ono, Japan.
Toshio ItohDepartment of Internal Medicine, Miki-Sanyo Hospital, Miki, Japan.
Takeshi SugimotoDepartment of Hematology/Oncology, Kita-Harima Medical Center, Ono, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a case report of a 60-year-old male patient with essential thrombocythemia (ET) that progressed to acute myeloid leukemia (AML) in approximately 9 years. His platelet count decreased approximately 8 years after ET treatment with hydroxyurea (HU) and aspirin. The dose of HU was reduced because of suspected myelosuppression due to HU; however, myelosuppression did not improve. Bone marrow examination revealed myelofibrosis; therefore, ruxolitinib was administered. Approximately 1 year later, his leukocyte and blast counts in the peripheral blood increased; thus, ET was judged to have progressed to AML-myelodysplasia-related change. Induction chemotherapy and consolidation therapy were initiated; however, the patient unfortunately failed to achieve complete remission. We then continued to administer salvage chemotherapy; however, his general condition worsened, and he died from cerebral hemorrhage. The karyotype at the onset of ET was 46,XY, which changed to 47,XY,del(7q),+8 at the time of AML diagnosis. In addition, genetic testing revealed

Indexed as

Acute myeloid leukemiaDeletion of chromosome 7qEssential thrombocythemia

Identifiers

PMID33776707
PMCPMC7983570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.